230 related articles for article (PubMed ID: 31553250)
1. Ceftobiprole: drug evaluation and place in therapy.
Giacobbe DR; De Rosa FG; Del Bono V; Grossi PA; Pea F; Petrosillo N; Rossolini GM; Tascini C; Tumbarello M; Viale P; Bassetti M
Expert Rev Anti Infect Ther; 2019 Sep; 17(9):689-698. PubMed ID: 31553250
[No Abstract] [Full Text] [Related]
2. Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA.
Horn KS; Danziger LH; Rodvold KA; Glowacki RC
Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):463-472. PubMed ID: 28264613
[TBL] [Abstract][Full Text] [Related]
3. Ceftobiprole for the treatment of pneumonia: a European perspective.
Liapikou A; Cillóniz C; Torres A
Drug Des Devel Ther; 2015; 9():4565-72. PubMed ID: 26316697
[TBL] [Abstract][Full Text] [Related]
4. Ceftobiprole medocaril for the treatment of community-acquired pneumonia.
Falcó V; Burgos J; Almirante B
Expert Opin Pharmacother; 2018 Sep; 19(13):1503-1509. PubMed ID: 30198789
[TBL] [Abstract][Full Text] [Related]
5. Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.
Syed YY
Drugs; 2014 Sep; 74(13):1523-42. PubMed ID: 25117196
[TBL] [Abstract][Full Text] [Related]
6. Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia.
Scheeren TW
Future Microbiol; 2015; 10(12):1913-28. PubMed ID: 26573022
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of ceftobiprole.
Grau S
Rev Esp Quimioter; 2019 Sep; 32 Suppl 3(Suppl 3):34-36. PubMed ID: 31364340
[TBL] [Abstract][Full Text] [Related]
8. Ceftobiprole for the treatment of pneumonia.
Cillóniz C; Dominedò C; Garcia-Vidal C; Torres A
Rev Esp Quimioter; 2019 Sep; 32 Suppl 3(Suppl 3):17-23. PubMed ID: 31364337
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia.
Lagacé-Wiens PR; Rubinstein E
Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):789-99. PubMed ID: 23590397
[TBL] [Abstract][Full Text] [Related]
10. Genotypic Characterization of Methicillin-Resistant Staphylococcus aureus Recovered at Baseline from Phase 3 Pneumonia Clinical Trials for Ceftobiprole.
Mendes RE; Deshpande LM; Costello AJ; Farrell DJ; Jones RN; Flamm RK
Microb Drug Resist; 2016 Jan; 22(1):53-8. PubMed ID: 26230870
[TBL] [Abstract][Full Text] [Related]
11. Ceftobiprole and pneumonia in adults admitted to the emergency department is it time to assess a new therapeutic algorithm?
Crapis M; Venturini S; Della Siega P; Tonizzo M; Garlatti E; Rosa R; Basso B; Pontoni E
J Chemother; 2021 May; 33(3):174-179. PubMed ID: 32996844
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations.
Torres A; Mouton JW; Pea F
Clin Pharmacokinet; 2016 Dec; 55(12):1507-1520. PubMed ID: 27272266
[TBL] [Abstract][Full Text] [Related]
13. Ceftobiprole: A novel, broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Dauner DG; Nelson RE; Taketa DC
Am J Health Syst Pharm; 2010 Jun; 67(12):983-93. PubMed ID: 20516468
[TBL] [Abstract][Full Text] [Related]
14. Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials.
Scheeren TWL; Welte T; Saulay M; Engelhardt M; Santerre-Henriksen A; Hamed K
BMC Infect Dis; 2019 Feb; 19(1):195. PubMed ID: 30808293
[TBL] [Abstract][Full Text] [Related]
15. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia.
Awad SS; Rodriguez AH; Chuang YC; Marjanek Z; Pareigis AJ; Reis G; Scheeren TW; Sánchez AS; Zhou X; Saulay M; Engelhardt M
Clin Infect Dis; 2014 Jul; 59(1):51-61. PubMed ID: 24723282
[TBL] [Abstract][Full Text] [Related]
16. Ceftobiprole Medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788.
Drugs R D; 2006; 7(5):305-11. PubMed ID: 16922591
[TBL] [Abstract][Full Text] [Related]
17. [Zinforo™ (ceftaroline fosamil)--A new beta-lactam-cephalosporin with MRSA activity].
Welte T
Dtsch Med Wochenschr; 2014 Nov; 139 Suppl 3():S89-90. PubMed ID: 25429539
[No Abstract] [Full Text] [Related]
18. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
[TBL] [Abstract][Full Text] [Related]
19. Ceftobiprole: a new broad spectrum cephalosporin.
El Solh A
Expert Opin Pharmacother; 2009 Jul; 10(10):1675-86. PubMed ID: 19527192
[TBL] [Abstract][Full Text] [Related]
20. Current and Future Considerations for the Treatment of Hospital-Acquired Pneumonia.
Montravers P; Harpan A; Guivarch E
Adv Ther; 2016 Feb; 33(2):151-66. PubMed ID: 26861846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]